In pivotal Phase III clinical trials, LUCENTIS® was administered once per month for up to 2 years. The benefits of treatment with LUCENTIS® were also maintained in most patients for up to 2 years with continuous use. Treatment should be continued and monitored. Individual results may vary.1  top

LUCENTIS® is indicated for the treatment of patients with neovascular (wet) age-related macular degeneration.1  top

In pivotal clinical trials, some patients reported an improvement in vision starting at day 7 after treatment with LUCENTIS®. Just because a patient does not report an immediate improvement, it does not mean that LUCENTIS® is not working. Some patients experience improvement later or merely do not lose significant vision with LUCENTIS®.1  top

The FDA-approved dose of LUCENTIS® is 0.5 mg (0.05 mL) administered by intravitreal injection. In pivotal Phase III clinical trials, LUCENTIS® was administered once a month. Dosing is at the discretion of the physician.1 Although less effective, treatment may be reduced to one injection every three months after the first four injections if monthly injections are not feasible.

LUCENTIS® has been studied in more than 1000 patients with neovascular age-related macular degeneration in 2 double-masked, controlled 2-year studies.1 LUCENTIS® (ranibizumab injection) is indicated for the treatment of patients with neovascular (wet) age-related macular degeneration.1 Intravitreal injections, including those with LUCENTIS®, have been associated with endophthalmitis and retinal detachment.

Lucentis is another anti-VEGF (vascular endothelial growth factor) drug designed to inhibit a growth factor that operates on blood vessels. It is injected into the eye every four weeks. Lucentis was approved for treatment of AMD by the FDA on June 30, 2006, after Genentech, the manufacturer, reported on May 23, 2005 that Lucentis either maintained or improved vision in 95% of patients with wet AMD participating in the Phase III trial.

In general, FDA-approved therapeutic agents are covered by Medicare for on-label indications if administered by a physician and determined reasonable and necessary for the patient's condition. Medicare covers use of LUCENTIS® when used in patients with a confirmed diagnosis of neovascular AMD. Please consult your local carrier for specific coverage information via http://cms.hhs.gov/.  top

Medicaid coverage for LUCENTIS® will be determined on a state-by-state level. Please contact your state Medicaid office for specific information on LUCENTIS® coding and billing guidelines for Medicaid patients. Please consult your local state Medicaid department for specific coverage information.  top

Reimbursement will vary by region, payer, and plan. Providers are advised to check with their local Medicare carrier or insurer to obtain specific reimbursement rates for use of LUCENTIS® and the intravitreal injection.  top Single Point of Contact (SPOC) does not submit claims on behalf of providers or facilities. However, Single Point of Contact (SPOC) does provide the following services: Identifies the appropriate specialty pharmacy to obtain LUCENTIS® (if needed).

The UI Hospitals admitted over 27,000 patients and there were over 856,000 clinic visits in the past year alone. There were 1,600 babies born at the hospital and 6 heart transplants last year. The UI Hospitals and Clinics is a teaching hospital that is funded by patient funds (including insurance funds) like most other hospitals in Iowa. It receives state funding to underwrite a portion of the training of Iowa physicians and to care for patients who qualify for state support.

We treat a diverse patient population from the surrounding community. Professional musicians, executive assistants, soccer moms, and elite athletes have all benefited from our professionalism, respect, and care. With a critical eye we aim to get you independent and pain free as quickly as possible.

Each 1 oz. bottle of Renewal® contains approximately 180 sprays and will last 5-6 weeks depending on the level of use.

Medicare Advantage plans typically provide benefits similar to traditional Medicare. However, Medicare Advantage plans might require prior authorization before treatment is administered. It is recommended that you check with the insurer to determine if these steps are necessary. Please consult your local carrier for specific coverage information via http://cms.hhs.gov/.  top

Commercial insurer benefits will vary by plan. Commercial payers may require prior authorization for certain drugs and/or procedures. It will be important to check with the insurer to determine if coverage for LUCENTIS® is provided and/or prior authorization is necessary.  top

Since a claim may be denied for various reasons, it is recommended that you review the establishment of benefits (EOB) thoroughly to understand why the claim was denied. The insurer might require additional documentation of medical necessity justifying use of LUCENTIS® (e.g. physician notes or product ordering invoices). Please see the LUCENTIS COMMITMENT—Access Made Simple™ Billing and Coding Guide for sample materials that could be used to appeal a denial.

It is recommended that you check with payers to determine if coverage for LUCENTIS® is provided when administered bilaterally on a single date of service. The safety and efficacy of LUCENTIS® therapy administered to both eyes on the same date of service has not been established. Physicians are advised to use their own discretion when determining the medical appropriateness of bilateral administration of LUCENTIS®.

When you use the entire system (The Derma Cleanse® capsules, Facial Cleansing Gel, and Acne Gel), you should start seeing fantastic results after about 6-8 weeks of consistent use. Remember that overnight cures are not possible with acne, you must be consistent with treatment and maintenance. We believe the results will be worth it.

Clot busters that dissolve a blood clot can be given if a stroke patient is brought to the hospital within three hours. Hence a person with suspected stroke should be brought to hospital as quick as possible. There are several therapies to prevent stroke recurrence such as "blood thinners" like aspirin, which will be decided by your physician. These medicines may have to be taken life long.

Initial government funded research and development work in cardiac-support systems in 1966. The company began clinical trials of the air-driven LVAS in 1986 and of the electric system in 1991. It has been used in patients ranging from age 11 to 78, with an average age of 51. The HeartMate device has been implanted in more than 4,100 patients at leading cardiac centers in the U.S. and overseas.

The Clinic plans to create a network of referrals for such cases. We hope to be able to refer patients to specialists that will treat our patients for free or at least at a reduced fee. Credentialing procedures will be in place for all healthcare/dental providers. Healthcare professionals will be required to provide the Clinic with appropriate state licensing information.

Drugs eliminated by non-renal routes – INH, Rifampicin, Pyrazinamide and Thioamides may be given in normal doses.

Answer: There is a dedicated therapy staff for pediatric and adult patients. The clinic staff treats patients of all ages.

Absolutely. We treat and have treated thousands of people. We give you the same advice that has been successful for our patients.

Yes. We are happy to see patients who are out of our network. However, the payment for the cost of the visit will be expected at the time of service.

Yes. Workman's compensation patients are always welcome in our office. The workman's compensation adjustor will need to call to schedule the appointment and we will work to see the patient is a timely fashion.

Yes we do. Patients drive from a few hours away, others fly across the country to visit our clinic. We accommodate these patients by extending their treatment length, so they will need to return less frequently. We will also coach our patients on how to maintain their health so we won’t need to see them as often.

Many horses are showing a response in 2 months but most will still need treatment for an additional 2-4 months. To determine if the tumor is gone, clean off the scabs and crusts very well. If you see any pink shiny bumps, you should continue treatment. Flat sarcoids are harder to monitor. For this kind you may want to stop treatment after 2-4 months and recheck it 30 days later to see what areas need further treating.

Results from the treatments available vary by person. Some people will see results from treatment within 3 to 6 months. Others may not see results for 8 months. With immunomodulators, some people are reporting some repigmentation with 4 to 8 weeks. For others it is taking longer. The rule of thumb, is that you will need to allow at least 3 to 6 months before you begin to see results from ANY treatment.

Patients scheduled for an endoscopic discectomy are requested to stay in California for three days. They will be seen for a consultation and surgery discussion on the first day, surgery will be performed on the second day, and they can return home on the third day after a post-operative visit with the doctor. Patients with open discectomies are requested to stay for at least two days post-operatively.

The longest study was 6 months. As long as patients continue the treatment, using the device routinely, the benefits in lowering blood pressure are maintained. There are people who have been using RESPeRATE for over five years and continue to maintain normal BP. In all clinical trials, blood pressure values were measured as next morning results and not directly after the intervention. A sustained, all-day reduction has been showed in a 24-hours ambulatory study.